Related Experiment Video
Updated: Oct 4, 2025
12:25
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
16.1K
Botulinum Toxin Type A Immunogenicity across Multiple Indications: An Overview Systematic Review
Eqram Rahman1, Pooja S Banerjee1, Andleeb Asghar1
1From the Department of Plastic and Reconstructive Surgery, Royal Free Hospital, University College London; Samarpit Hospital; and Faculty of Pharmaceutical and Allied Health Sciences, Institute of Pharmacy, Lahore College for Women University.
Plastic and Reconstructive Surgery
|February 9, 2022
Summary
Neutralizing antibody formation from botulinum toxin type A is low across all formulations, though higher in certain medical conditions. Further research is needed to compare products and clinical relevance.
Area of Science:
- Neurology
- Immunology
- Dermatology
Background:
- Botulinum toxin type A is widely used for neurologic, medical, and aesthetic conditions.
- Factors like dosage, treatment intervals, and protein content influence neutralizing antibody formation.
- Understanding antibody prevalence is crucial for optimizing therapeutic outcomes.
Purpose of the Study:
- To synthesize evidence on neutralizing antibody prevalence across botulinum toxin type A formulations.
- To assess the quality of existing systematic reviews on this topic.
- To identify gaps in knowledge regarding antibody formation and clinical response.
Main Methods:
- An overview of systematic reviews following Cochrane guidelines.
- Critical appraisal of five systematic reviews using the AMSTAR-2 tool.
- Analysis of data from 203 studies involving 17,815 patients.
Main Results:
- Systematic reviews included had low to critically poor AMSTAR-2 scores, indicating high heterogeneity.
- Neutralizing antibody prevalence was higher in dystonia, spasticity, and urologic conditions, but low in hyperhidrosis and aesthetic uses.
- Overall neutralizing antibody formation rates were 1-2.1% across abobotulinumtoxinA, incobotulinumtoxinA, and onabotulinumtoxinA, with no significant differences.
Conclusions:
- The overall frequency of neutralizing antibodies and immunogenicity for major botulinum toxin type A products remain low.
- Well-designed comparative trials are necessary to differentiate antibody prevalence among commercial formulations.
- Future studies should investigate the clinical significance of neutralizing antibody titers on treatment efficacy.
